Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin in AD and MCI (SNIFF 120)
NCT00438568Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jun 2006
- Primary completion
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human insulin in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by University of Washington. Primary endpoint: Cognition at 24 weeks. Started Jun 2006; status: completed.
02
Drugs
human insulin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00438568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00438568.